METODOLOGIChESKIE ASPEKTY MORFOLOGIChESKOY DIAGNOSTIKI I OTsENKI LEChEBNOGO PATOMORFOZA TROYNOGO NEGATIVNOGO RAKA MOLOChNOY ZhELEZY


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Molecular and genetic types of breast cancer are described. Particular attention is paid to the tumors with triple-negative phenotype, including basal-like subtype. The requirements to the biopsy sampling and material processing necessary for immunohistochemistry are presented. The importance of assessment of therapeutic pathomorphism using different systems of evaluation of response to therapy is demonstrated.

Full Text

Restricted Access

References

  1. Кулигина Е.Ш. Эпидемиологические и молекулярные аспекты рака молочной железы. Практическая онкология. 2010; 11(4): 203-16.
  2. Perou C.M., Sorlie T., Eisen M.B., et al. Molecular portraits of human breast tumours. Nature. 2000; 406(6797): 747-52.
  3. Bidard F.C., Conforti R., Boulet T., et al. Does triple-negative phenotype accurately identify basal-like tumour? An immunohistochemical analysis based on 143 «triple-negative» breast cancers. Ann Oncol. 2007; 18(7): 1285-86.
  4. Keam B., Im S.A., Kim H.J., et al. Prognostic impact of clinicopathologic parameters in stage II/III breast cancer treated with neoadjuvant docetaxel and doxorubicin chemotherapy: paradoxical features of the triple negative breast cancer. BMC Cancer. 2007; 7: 203.
  5. Bauer K.R., Brown M., Cress R.D., Parise C.A., Caggiano V. Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry. Cancer. 2007; 109(9): 1721-28.
  6. Kreike B., van Kouwenhove M., Horlings H., et al. Gene expression profiling and histopathological characterization of triple-negative/basal-like breast carcinomas. Breast Cancer Res. 2007; 9(5): R65.
  7. Parker J.S., Mullins M., Cheang M.C., et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. J. Clin. Oncol. 2009; 27(8): 1160-67.
  8. Жукова Л.Г. Наиболее значимые успехи в лечении рака молочной железы за 2011 год. Практическая онкология. 2012; 13(1 ): 22-31.
  9. Жукова Л.Г. Современные возможности терапии метастатического рака молочной железы с тройным негативным фенотипом. Большая конференция RUSSCO «Рак молочной железы» (22-24 января 2014) http://www.rosoncoweb.ru/events/2014/01/22/archive/
  10. Cheang M.C., Voduc D., Bajdik C., et al. Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype. Clin. Cancer Res. 2008; 14(5): 1368-76.
  11. Поддубная И.В., Карселадзе Д.А. «Тройной негативный» рак молочной железы. Вестник РОНЦ им. Н.Н. Блохина РАМН. 2009; 20(3): 12-20.
  12. Cleator S., Heller W., Coombes R.C. Triple-negative breast cancer: therapeutic options. Lancet Oncol. 2007; 8(3): 235-44.
  13. Morris G.J., Naidu S., Topham A.K., et al. Differences in breast carcinoma characteristics in newly diagnosed African-American and Caucasian patients: a singleinstitution compilation compared with the National Cancer Institute's Surveillance, Epidemiology, and End Results database. Cancer. 2007; 110(4): 876-84.
  14. Wetzels R.H., Holland R., van Haelst U.J., et al. Detection of basement membrane components and basal cell keratin 14 in noninvasive and invasive carcinomas of the breast. Am. J. Pathol. 1989; 134(3): 5 71-79.
  15. Calza S., Hall P., Auer G., et al. Intrinsic molecular signature of breast cancer in a population-based cohort of 412 patients. Breast Cancer Res. 2006; 8(4): R34.
  16. Hu Z., Fan C., Oh D.S., et al. The molecular portraits of breast tumors are conserved across microarray platforms. BMC Genomics. 2006; 7: 96.
  17. Sorlie T., Tibshirani R., Parker J., et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc. Natl. Acad. Sci. (USA). 2003; 100(14): 8418-23.
  18. Livasy C.A., Perou C.M., Karaca G., et al. Identification of a basal-like subtype of breast ductal carcinoma in situ. Hum. Pathol. 2007; 38(2): 197-204.
  19. Rodriguez-Pinilla S.M., Rodriguez-Gil Y., Moreno-Bueno G., et al. Sporadic invasive breast carcinomas with medullary features display a basal-like phenotype: an immunohistochemical and gene amplification study. Am. J. Surg. Pathol. 2007; 31(4): 501-08.
  20. Rodriguez-Pinilla S.M., Sarrio D., Honrado E., et al. Vimentin and laminin expression is associated with basal-like phenotype in both sporadic and BRCA1 -associated breast carcinomas. J. Clin. Pathol. 2007; 60(9): 1006-12.
  21. Reis-Filho J.S. and Tutt A.N. Triple negative tumours: a critical review. Histopathology. 2008; 52(1): 108-18.
  22. Kim M.J., Ro J.Y., Ahn S.H., et al. Clinicopathologic significance of the basal-like subtype of breast cancer: a comparison with hormone receptor and Her2/neu-overexpressing phenotypes. Hum. Pathol. 2006; 37(9): 1217-26.
  23. Potemski P., Kusinska R., Watala C., et al. Prognostic relevance of basal cytokeratin expression in operable breast cancer. Oncology. 2005; 69(6): 478-85.
  24. Fadare, O. and Tavassoli, F.A. The phenotypic spectrum of basal-like breast cancers: a critical appraisal. Adv Anat. Pathol. 2007; 14(5): 358-73.
  25. Seewaldt V.L., Scott V. Images in clinical medicine. Rapid progression of basal-type breast cancer. N. Engl. J. Med. 2007; 356(13): e12.
  26. Стенина М.Б., Фролова М., Скрыпникова М., Тюляндин С.А. Базальноподобный (тройной негативный) рак молочной железы: молекулярные особенности, течение и возможные терапевтические подходы. Врач. 2010; 3: 24-8.
  27. Bergamaschi A., Kim Y.H., Wang P., et al. Distinct patterns of DNA copy number alteration are associated with different clinicopathological features and gene-expression subtypes of breast cancer. Genes Chromosomes Cancer. 2006; 45(11): 1033-40.
  28. Chin K., DeVries S., Fridlyand J., et al. Genomic and transcriptional aberrations linked to breast cancer pathophysiologies. Cancer Cell. 2006; 10(6): 529-41.
  29. Rouzier R., Perou C.M., Symmans W.F., et al. Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin. Cancer Res. 2005; 11(16): 5678-85.
  30. Abrial S.C., Penault-Llorca F., Delva R., et al. High prognostic significance of residual disease after neoadjuvant chemotherapy: a retrospective study in 710 patients with operable breast cancer. Breast Cancer Res. Treat. 2005; 94(3): 255-63.
  31. Fisher E.R., Wang J., Bryant J., et al. Pathobiology of preoperative chemotherapy: findings from the National Surgical Adjuvant Breast and Bowel (NSABP) protocol B-18. Cancer. 2002; 95(4): 681-95.
  32. Chevallier B., Roche H., Olivier J.P., et al. Inflammatory breast cancer. Pilot study of intensive induction chemotherapy (FEC-HD) results in a high histologic response rate. Am J Clin Oncol 1993; 16(3): 223-28.
  33. Sataloff D.M., Mason B.A., Prestipino A.J., et al. Pathologic response to induction chemotherapy in locally advanced carcinoma of the breast: a determinant of outcome. J. Am. Coll. Surg. 1995; 180(3): 297-306.
  34. Ogston K.N., Miller I.D., Payne S., et al. A new histological grading system to assess response of breast cancers to primary chemotherapy: prognostic significance and survival. Breast. 2003; 12(5): 320-07.
  35. Symmans W.F., Peintinger F., Hatzis C., et al. Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. J. Clin. Oncol. 2007; 25(28): 4414-22.
  36. Carey L.A., Metzger R., Dees E.C., et al. American Joint Committee on Cancer tumor-node-metastasis stage after neoadjuvant chemotherapy and breast cancer outcome. J. Natl. Cancer Inst. 2005; 97(15): 1137-42.
  37. Le Doussal V., Tubiana-Hulin M., Friedman S., et al. Prognostic value of histologic grade nuclear components of Scarff-Bloom-Richardson (SBR). An improved score modification based on a multivariate analysis of 1262 invasive ductal breast carcinomas. Cancer. 1989; 64(9): 1914-21.
  38. Pinder S.E., Provenzano E., Earl H., Ellis I.O. Laboratory handling and histology reporting of breast specimens from patients who have received neoadjuvant chemotherapy. Histopathology. 2007; 50(4): 409-17.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2014 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies